BiotechTube

Pemvidutide

Phase 2Active
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Alcohol Use Disorder (AUD)

Conditions

Alcohol Use Disorder (AUD)

Trial Timeline

May 15, 2025 → Jun 1, 2026

NCT ID
NCT06987513

About Pemvidutide

Pemvidutide is a phase 2 stage product being developed by Altimmune for Alcohol Use Disorder (AUD). The current trial status is active. This product is registered under clinical trial identifier NCT06987513. Target conditions include Alcohol Use Disorder (AUD).

What happened to similar drugs?

11 of 20 similar drugs in Alcohol Use Disorder (AUD) were approved

Approved (11) Terminated (2) Active (8)
✅Seroquel XRAstraZenecaApproved
✅Acamprosate or NaltrexoneMerckApproved
✅Acamprosate + PlaceboMerckApproved
✅LevetiracetamUCBApproved
✅losartan (drug)LundbeckApproved
✅Selincro® 18 mg with continuous psychosocial support: Cohort ALundbeckApproved
✅nalmefeneLundbeckApproved

Hype Score Breakdown

Clinical
12
Activity
12
Company
5
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT07009860Phase 2Recruiting
NCT06987513Phase 2Active

Competing Products

20 competing products in Alcohol Use Disorder (AUD)

See all competitors
ProductCompanyStageHype Score
VK2809 + PlacebosViking TherapeuticsPhase 2
32
TERN-501 + TERN-101Terns PharmaceuticalsPhase 2
32
TERN-101Terns PharmaceuticalsPhase 2
32
TERN-201Terns PharmaceuticalsPhase 1
26
IVA337 + IVA337 + PlaceboInventivaPhase 2
29
LanifibranorInventivaPhase 2
29
IVA337 + Placebo + EmpagliflozinInventivaPhase 2
29
IVA337 + PlaceboInventivaPhase 3
41
LY686017 + PlaceboEli LillyPhase 2
35
LY3537031 + PlaceboEli LillyPhase 3
47
AD04 (ondansetron) + Matching placeboAdial PharmaceuticalsPhase 3
30
GODEX + PlaceboCelltrionPhase 3
47
Colesevelam HclDaiichi SankyoPhase 2
35
ASP9831 + PlaceboAstellas PharmaPhase 2
35
ASP8062 + PlaceboAstellas PharmaPhase 2
35
LY686017 + PlaceboEli LillyPhase 2
35
Mazdutide + PlaceboEli LillyPhase 2
42
opioid receptor kappa antagonistEli LillyPhase 1
29
Tirzepatide + PlaceboEli LillyPhase 2
35
LY2196044 + placeboEli LillyPhase 2
35